Macrophage inflammatory protein-1
Macrophage inflammatory protein-1
复制标题
DOI：
10.1016/j.biocel.2003.10.019
复制
发表时间：
2004-10-01
影响因子：
4
通讯作者：
von Stebut, E
中科院分区：
文献类型：
--
作者：
Maurer, M;von Stebut, E
巨噬细胞炎症蛋白(MIP)-1alpha于15年前被发现，是MIP-1 CC趋化因子亚家族四个成员中的第一个。这些蛋白被称为CCL3 （mip -1 α）、CCL4 （mip -1 β）、CCL9/10 （mip -1 δ）和CCL15 (mip -1 γ)，根据修订的趋化因子命名法，这些蛋白由许多细胞产生，特别是巨噬细胞、树突状细胞和淋巴细胞。MIP-1蛋白通过g蛋白偶联细胞表面受体（ccr1,3,5）起作用，例如由淋巴细胞和单核/巨噬细胞（MPhi）表达，以其趋化和促炎作用而闻名，但也可以促进体内平衡。在小鼠炎症模型（如哮喘、关节炎或多发性硬化症）中进行的临床前研究取得了令人鼓舞的结果，导致了强效CCR3和5拮抗剂的开发，其中一些药物目前正在进行首次临床试验。(C) 2003 Elsevier Ltd.版权所有。
Macrophage inflammatory protein (MIP)-1alpha was identified 15 years ago as the first of now four members of the MIP-1 CC chemokine subfamily. These proteins termed CCL3 (MIP-1alpha), CCL4 (MIP-1beta), CCL9/10 (MIP-1delta), and CCL15 (MIP-1gamma) according to the revised nomenclature for chemokines are produced by many cells, particularly macrophages, dendritic cells, and lymphocytes. MIP-1 proteins, which act via G-protein-coupled cell surface receptors (CCR1, 3, 5), e.g. expressed by lymphocytes and monocytes/macrophages (MPhi), are best known for their chemotactic and proinflammatory effects but can also promote homoeostasis. The encouraging results of preclinical studies in murine models of inflammation, i.e. asthma, arthritis, or multiple sclerosis, have led to the development of potent CCR3 and 5 antagonists, some of which are currently being tested in first clinical trials. (C) 2003 Elsevier Ltd. All rights reserved.